Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19884
Full metadata record
DC FieldValueLanguage
dc.contributor.authorParakh, Sagun-
dc.contributor.authorRandhawa, Manreet-
dc.contributor.authorNguyen, Bella-
dc.contributor.authorWarburton, Lydia-
dc.contributor.authorHussain, Mohammad Akhtar-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorMillward, Michael-
dc.contributor.authorYip, Desmond-
dc.contributor.authorAli, Sayed-
dc.date2018-11-13-
dc.date.accessioned2018-11-26T00:51:14Z-
dc.date.available2018-11-26T00:51:14Z-
dc.date.issued2019-02-
dc.identifier.citationAsia-Pacific journal of clinical oncology 2019; 15(1): 26-30-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19884-
dc.description.abstractThere is limited real-world data on the efficacy and safety of combination programmed cell death protein-1 (PD-1) inhibitor, nivolumab and the cytotoxic T-lymphocyte antigen (CTLA-4) inhibitor ipilimumab. We retrospectively identified patients (pts) with metastatic melanoma treated with three-weekly nivolumab (1 mg/kg) in combination with ipilimumab (3 mg/kg) for four cycles followed by nivolumab monotherapy (3 mg/kg) fortnightly. Patient demographics and treatment parameters were collected and outcomes determined. A total of 45 pts received combination treatment with a median follow up of 8.7 months (range 0.33-25.9 months). A total of 67% were male, and BRAF V600 mutations detected in 38%. At treatment commencement, 14 (31%) pts had brain metastases, 51% had an elevated LDH and 18 (40%) were treatment-naive. Almost a third (30%) required corticosteroids for symptom control or management of prior toxicities. Nineteen (42%) patients had prior anti-PD-1 therapy. The disease control rate (DCR) was 54% and objective response rate (ORR) was 29%. Of pts treated with prior immune checkpoint inhibitors, the DCR and ORR were 50% and 33%, respectively. Intracranial responses were observed in 18% (n = 2). The median progression-free survival (PFS) was 5.8 months (95% Confidence interval (CI), 2.9-14.1 months). PFS was higher in treatment naïve patients compared to those who had prior immunotherapy (6.2 months vs 4.9 months, P = 0.59). The median OS was 17.4 months (95% CI, 7.1-NR). pts requiring corticosteroids had a shorter PFS (4.9 months vs 6.8 months) and OS (7.1 months vs NR, P = 0.01).Treatment-related adverse events of any grade were experienced by 88% of pts, with 54% having grade 3-4 adverse events. Treatment discontinuation due to adverse events occurred in 44% of pts. In this study, responses to combination immunotherapy were lower than reported. Patients treated with prior immunotherapy had similar responses as treatment-naïve pts. The toxicity profile seen in this study is similar to those reported in clinical trials.-
dc.language.isoeng-
dc.subjectipilimumab-
dc.subjectmetastatic melanoma-
dc.subjectnivolumab-
dc.titleReal-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.-
dc.typeJournal Article-
dc.identifier.journaltitleAsia-Pacific journal of clinical oncology-
dc.identifier.affiliationDepartment of Medical Oncology, Sir Charles Gairdner Hospital, WA, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationANU Medical School, Australian National University, ACT, Australiaen
dc.identifier.affiliationSchool of Population and Global Health, University of Western Australia, WA, Australiaen
dc.identifier.affiliationWestern Australia Centre for Rural Health, University of Western Australia, WA, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Canberra Region Cancer Centre, The Canberra Hospital, ACT, Australiaen
dc.identifier.doi10.1111/ajco.13100-
dc.identifier.orcid0000-0003-3891-2489-
dc.identifier.orcid0000-0003-0045-6027-
dc.identifier.orcid0000-0002-6012-3702-
dc.identifier.pubmedid30426665-
dc.type.austinJournal Article-
local.name.researcherCebon, Jonathan S
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.